Loading...
•
Sep 30, 2021
Ovid Therapeutics Q3 2021 Earnings Report
Ovid reported Q3 2021 results, strategic intent to pursue business development opportunities and confirmed desired areas of business development to apply its capital and expertise.
Key Takeaways
Ovid Therapeutics reported zero revenue for the quarter ended September 30, 2021, compared to $6.9 million for the same period in 2020. Research and development expenses were $4.9 million, compared to $15.9 million for the same period in 2020. The company's cash and cash equivalents were $201.8 million as of September 30, 2021.
Implementing business development program to enhance pipeline of CNS medicines.
Soticlestat development program (licensed to Takeda) has begun enrolling patients in Phase 3 trials.
Company ended the quarter with $201.8 million in cash and cash equivalents.
Strategic review of potential programs confirmed desired areas of business development.
Forward Guidance
Ovid expects non-GAAP adjusted operating expenses to remain within the $8.0—$10.0 million range for the fourth quarter of 2021.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...